Literature DB >> 20096298

Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart.

David Montaigne1, Xavier Marechal, Riadh Baccouch, Thomas Modine, Sebastien Preau, Konstantinos Zannis, Philippe Marchetti, Steve Lancel, Remi Neviere.   

Abstract

The present study was undertaken to examine the effects of doxorubicin on left ventricular function and cellular energy state in intact isolated hearts, and, to test whether inhibition of mitochondrial membrane potential dissipation would prevent doxorubicin-induced mitochondrial and myocardial dysfunction. Myocardial contractile performance and mitochondrial respiration were evaluated by left ventricular tension and its first derivatives and cardiac fiber respirometry, respectively. NADH levels, mitochondrial membrane potential and glucose uptake were monitored non-invasively via epicardial imaging of the left ventricular wall of Langendorff-perfused rat hearts. Heart performance was reduced in a time-dependent manner in isolated rat hearts perfused with Krebs-Henseleit solution containing 1 microM doxorubicin. Compared with controls, doxorubicin induced acute myocardial dysfunction (dF/dt(max) of 105+/-8 mN/s in control hearts vs. 49+/-7 mN/s in doxorubicin-treated hearts; p<0.05). In cardiac fibers prepared from perfused hearts, doxorubicin induced depression of mitochondrial respiration (respiratory control ratio of 4.0+/-0.2 in control hearts vs. 2.2+/-0.2 in doxorubicin-treated hearts; p<0.05) and cytochrome c oxidase kinetic activity (24+/-1 microM cytochrome c/min/mg in control hearts vs. 14+/-3 microM cytochrome c/min/mg in doxorubicin-treated hearts; p<0.05). Acute cardiotoxicity induced by doxorubicin was accompanied by NADH redox state, mitochondrial membrane potential, and glucose uptake reduction. Inhibition of mitochondrial permeability transition pore opening by cyclosporine A largely prevented mitochondrial membrane potential dissipation, cardiac energy state and dysfunction. These results suggest that in intact hearts an impairment of mitochondrial metabolism is involved in the development of doxorubicin cardiotoxicity. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096298     DOI: 10.1016/j.taap.2010.01.006

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  20 in total

1.  The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle.

Authors:  Laura A A Gilliam; Kelsey H Fisher-Wellman; Chien-Te Lin; Jill M Maples; Brook L Cathey; P Darrell Neufer
Journal:  Free Radic Biol Med       Date:  2013-09-07       Impact factor: 7.376

2.  CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis.

Authors:  Ting Zhang; Yan Zhang; Mingyao Cui; Li Jin; Yimei Wang; Fengxiang Lv; Yuli Liu; Wen Zheng; Haibao Shang; Jun Zhang; Mao Zhang; Hongkun Wu; Jiaojiao Guo; Xiuqin Zhang; Xinli Hu; Chun-Mei Cao; Rui-Ping Xiao
Journal:  Nat Med       Date:  2016-01-04       Impact factor: 53.440

3.  Cardiac systolic dysfunction in doxorubicin-challenged rats is associated with upregulation of MuRF2 and MuRF3 E3 ligases.

Authors:  Marcia Gracindo da Silva; Elisabete Mattos; Juliana Camacho-Pereira; Tatiana Domitrovic; Antonio Galina; Mauro W Costa; Eleonora Kurtenbach
Journal:  Exp Clin Cardiol       Date:  2012-09

4.  Sulforaphane protects the heart from doxorubicin-induced toxicity.

Authors:  Preeti Singh; Rajendra Sharma; Kevin McElhanon; Charles D Allen; Judit K Megyesi; Helen Beneš; Sharda P Singh
Journal:  Free Radic Biol Med       Date:  2015-05-27       Impact factor: 7.376

Review 5.  The continuing evolution of the Langendorff and ejecting murine heart: new advances in cardiac phenotyping.

Authors:  Ronglih Liao; Bruno K Podesser; Chee Chew Lim
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-05-25       Impact factor: 4.733

6.  Mitochondrial accumulation of doxorubicin in cardiac and diaphragm muscle following exercise preconditioning.

Authors:  Aaron B Morton; Andres Mor Huertas; J Matthew Hinkley; Noriko Ichinoseki-Sekine; Demetra D Christou; Ashley J Smuder
Journal:  Mitochondrion       Date:  2018-02-21       Impact factor: 4.160

Review 7.  Guidelines for evaluating myocardial cell death.

Authors:  Paras K Mishra; Adriana Adameova; Joseph A Hill; Christopher P Baines; Peter M Kang; James M Downey; Jagat Narula; Masafumi Takahashi; Antonio Abbate; Hande C Piristine; Sumit Kar; Shi Su; Jason K Higa; Nicholas K Kawasaki; Takashi Matsui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-16       Impact factor: 4.733

Review 8.  Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches.

Authors:  Mohammad Sheibani; Yaser Azizi; Maryam Shayan; Sadaf Nezamoleslami; Faezeh Eslami; Mohammad Hadi Farjoo; Ahmad Reza Dehpour
Journal:  Cardiovasc Toxicol       Date:  2022-01-21       Impact factor: 3.231

9.  Evaluation of the phytochemical composition and protective activities of methanolic extracts of Centaurea borysthenica and Centaurea daghestanica (Lipsky) Wagenitz on cardiomyocytes treated with doxorubicin.

Authors:  Agnieszka Korga; Aleksandra Józefczyk; Grażyna Zgórka; Mateusz Homa; Marta Ostrowska; Franciszek Burdan; Jarosław Dudka
Journal:  Food Nutr Res       Date:  2017-07-06       Impact factor: 3.894

10.  Panax notoginseng Saponin Protects Against Diabetic Cardiomyopathy Through Lipid Metabolism Modulation.

Authors:  Chenyang Zhang; Bin Zhang; Xuelian Zhang; Min Wang; Xiaobo Sun; Guibo Sun
Journal:  J Am Heart Assoc       Date:  2022-02-03       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.